ABSTRACT
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a cryptogenic but lethal disease. Characterized by exaggerating matrix deposition, lung architecture distortion and honeycombing, IPF results in loss of functional lung volume and gas exchanging capacity. Patients with late-stage IPF mostly die for respiratory failure, accompanying cardiac diseases or lung infections. Whereas the incidence of IPF seems to be low (approximately 2 to 29 cases per 100, 000 individuals), the 5-year survival rate of confirmed IPF patients who receive lung transplantation or not has never exceeded 50%, which is even lower than many malignancies [1, 2] .
Over the past decade, major accomplishments have been achieved in deciphering, diagnosing and treating IPF, as many new drugs and clinical guidelines have been advanced and utilized in IPF patients [3, 4] . Clinical trials have tested a number of single or combination drug therapies, among which the approval of pifernidone in Asia and Europe represents a milestone of overwriting clinical guidelines [5, 6] . Frustratingly, the mortality of IPF is still rising regardless of these advances [7] . This dilemma of drug therapies could largely be attributed to the unstoppable, deregulated remodeling process. Neither septa thickening nor alveolar distortion could be reversed with the prescription of any existing drugs including pirfenidone. Thus, pathological cure of IPF is almost impossible currently. Agreements have been made accordingly that the endpoints of clinical trials should no longer be ideally preventing from further disease progression, but more practically, stabilizing lung function and exercise capacities [8] .
In spite of these obstacles, stem cell therapy has shed some new lights on the management of IPF. Experts' agreements have been achieved favoring stem cell therapy in chronic airway diseases and pulmonary fibrosis [9] [10] [11] . The therapeutic role of mesenchymal stem cells (MSCs) has been implicated in serial processes of lung injury-repair disequilibrium and abnormal remodeling, including experimental lung fibrosis [12] [13] [14] [15] [16] [17] [18] [19] . Moreover, clinical trials have been launched to investigate the clinical safety and efficacy of MSCs in IPF patients [20, 21] . It is thus worthwhile to anticipate the possible bedside use of stem cells in pulmonary fibrosis in the future [22] [23] [24] . Here we review the up-to-date use of stem cells in experimental pulmonary fibrosis and its potential implications in the clinical settings. [29, 30] . Mesenchymal stem cells (MSC) could be isolated from various tissues including bone marrow, placenta, adipose tissue, and human cord blood. They are able to differentiate into bone, cartilage and fat, and may also aid in the regeneration of tissues [31] . The International Society of Cellular Therapy defined MSC by simultaneously meeting the following three criteria: (1) be adherent to plastic under standard tissue culture conditions; (2) expressing cell surface markers including CD105, CD90, and CD73, and should be negative for other surface markers, including CD45, CD34, CD14, and CD11b; (3) be capable of differentiating into mesenchymal lineages (osteoblasts, chondroblasts and adipocytes) under appropriate in vitro conditions [32] . MSCs are low immunogenic, since they constitutively express low levels of MHC I and II proteins, and are generally lack of T-cell costimulatory molecules such as CD80 and CD86 [33] . Therefore, allogeneic MSC are usually well tolerated by the host [10, 11, 33] . MSCs are able to recruit into the inflamed sites. They modulate the inflammatory process via suppressing T cell proliferation, secreting an array of antiapoptic, anti-inflammatory and angiogenic factors, and possibly, differentiating into tissue cells [34, 35] . After in vitro incubation with specific growth factors, human cord blood-derived mesenchymal stem cells (CBMSCs) are able to express Clara cell secretory protein (CCSP), cystic fibrosis transmembrane conductance regulator (CFTR), surfactant protein C, and thyroid transcription factor-1 mRNA, and CCSP and CFTR protein, suggesting the acquisition of alveolar epithelial phenoltype [36] . MSC engraftment ameliorates inflammation and facilitates tissue regeneration, and alleviates fibrosis in models of renal and myocardial injury [37] [38] [39] . Additionally, the anti-fibrotic property of MSC is also observed in experimental pulmonary fibrosis.
RATIONALES FOR STEM

Preclinical Studies of Stem Cells in Pulmonary Fibrosis
The hallmark histopathological pattern of IPF is usual interstitial pneumonia (UIP) [40] . The exact mechanism underlining IPF/UIP remains unknown. However, the hypothesis has become widely accepted that the convergence of intrinsic genetic predispositions and extrinsic irritants leads to continuous epithelial injury, which further initiates an abnormal fibrosing process that is characterized by activation of fibroblasts and excessive collagen synthesis [41] [42] [43] . To date there are no animal models exactly mimicking the pathological process of UIP, but bleomycin-induced lung injury and fibrosis is most relevant and has been widely used [44, 45] . Both IPF and bleomycin-induced experimental pulmonary fibrosis are characterized, and possibly induced, by lung epithelial apoptosis [46, 47] . There are also evidences that lung epithelial stem cells are exhausted and fail to maintain adequate repair in IPF and bleomycin-induced pulmonary fibrosis [48, 49] . Accumulating data obtained from animal studies has identified the curing role of stem cells in experimental lung fibrosis. Intravenous injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) significantly reduced bleomycin-induced increase in wet/ dry ratio, degree of neutrophilic infiltration, collagen deposition, and levels of the cytokines and nitric oxide [50] . Another study indicates that intravenous mesenchymal stem cell transfer reduces bleomycin injectioninduced expressions of TGF-beta1, PDGF-A, PDGF-B, and IGF-1 mRNA, and that some MSC engrafts presenting in injured lung tissue are positive for pan-cytokeratin staining, which indicates the differentiation of MSCs into alveolar epithelial cells in vivo [51] . MSCs inhibit the inflammatory responses and cellular injuries, and may differentiate into epithelial-like cells. These capabilities are assumed as their mechanisms which reverse experimental pulmonary fibrosis in animals [52] . The anti-inflammatory and anti-fibrotic capabilities are also presented in amnion epithelial cells, placenta-derived cells, umbilical cord mesenchymal stem cells and adiposederived stem cells (ADSCs) [53] [54] [55] [56] [57] [58] [59] . Interestingly, ESC engraftment also ameliorates experimental pulmonary fibrosis, although clinical research using ESCs is forbidden at the current time [60, 61] .
CLINICAL INVESTIGATIONS OF STEM CELLS IN IPF
Former clinical studies have demonstrated the efficacy and safety of a commercially available MSC product (prochymal, Osiris Therapeutics Inc., Columbia, MA) in patients with ischemic cardiomyopathy [62, 63] . A recently published trial assessed the safety and potential efficacy of intravenous infusion of MSCs (108 cells per infusion, once per month for consecutively 4 months) on patients with moderate to severe chronic obstructive pulmonary disease (COPD). Sixty-two patients were randomized to the MSC group or control group, all of whom completed the infusion protocol, and 74% completed the 2-year follow-up. No deaths, serious adverse events or infusion-related toxicities were closely related to MSC administration. MSC infusion was not correlated with disease exacerbations or increase of side effects. There were no significant differences in lung function parameters or quality-of-life indicators. MSC infusion results in an early, significant decrease in levels of circulating C-reactive protein who had elevated CRP levels at study entry [64] . There are no published trials about the use of stem cells in IPF patients. Nonetheless, a few studies might provide some evidences in the next future. Tzouvelekis et al (2011) have launched a trial to evaluate the safety, lung toxicity, patients' tolerability and antiinflammatory activity of endobronchial autologous infusion of ADSCs in IPF patients [20] . Compared with MSCs, ADSCs also have shown migratory, differentiative and fibro-sisreparative capacities, which are more easily isolated and enriched from adipose tissue, and are able to proliferate ex vivo. In this ongoing prospective, single-centered, nonrandomized clinical trial, well-selected patients would be randomized to the ADSC engraftment group and the control group. ADSCs are isolated via lipoaspiration autologously. Platelet rich plasma is prepared from blood simultaneously. ADSCs are activated by firstly coculture with platelet rich plasma and then by low-level laser irradiation, and are labeled with 99m Tc-ceretec thereafter. ADSC engraftment group would receive endobronchial infusion of ADSCs suspended in 10 ml aliquot (low treatment level: 0.5 × 10 6 cells/kg; high treatment level: 0.5 × 10 6 cells/kg) in both lower lobes, monthly for consecutive three months. Primary endpoints are safety and undesirable side effects, which include contaminations, neoplasia, fever, ectopic tissue formation, disease exacerbation, allergy, toxicity, and so on. Secondary endpoints denoting efficacy, are classified as clinical (arterial blood gases, dyspnea scales, quality of life), functional (6-minute walk test and lung function parameters) and radiological alterations (evaluated by high-resolution computed tomography). The safety of the procedures is partially witnessed by a preceding, small-scare preliminary trial which aims to visualize the 
CHALLENGES AND FUTURE DIRECTIONS FOR THE BENCH-TO-BEDSIDE TRANSLATION
How to Evaluate the Efficacy
Idiopathic interstitial pneumonias, including IPF, have been defined as three-facetted diseases manifesting different clinical, radiological and pathological features. Since pathological resolution is unnecessarily reached in almost all clinical trials about IPF, focus should be spent more on radiological, especially, functional and clinical improvements. In the new era of translational medicine, the endpoints of clinical trials on IPF are switching from preventing from further disease progression to stabilizing lung function and exercise capacities [8, 65] . More emphasis should be drawn on the functional status of patients, as well as the development and usage of biomarkers, instead of focusing in the reversal of the pathological alterations [66] . Importantly also, a great gap always exists between experimental pulmonary fibrosis and human IPF. Bleomycin-induced lung injury is characterized by marked acute pulmonary inflammation lasting for about 10 days, and subsequent fibrosis develops in 2 to 3 weeks but seldom progresses thereafter. In contrast, the process of lung injury and repair is consistent, and lung fibrosis is chronically and desperately progressing for months or years in human IPF [67, 68] . There emerge arguments that bleomycin-induced experimental pulmonary fibrosis does not necessarily represent similar changes in IPF [69] . In this viewpoint, the success of stem cell engraftment in animal models of pulmonary fibrosis does not necessarily warrant its therapeutic role in IPF patients [70] . Another concern arises that, a large proportion of IPF patients are diagnosed at the middle or late stage of disease, whose lung architectures are distorted and full of fibrosis and honeycombing. On the other hand though, MSC engraftment does not sufficiently attenuate bleomycin-induced lung fibrosis at the late stage (eg. 21-days after bleomycin exposure, unpublished data). The preliminary study of MSCs in COPD patients shows their anti-inflammatory efficacy but no improvements in disease exacerbations, lung function parameters or health-related quality-of-life. Taken these together, we might not be too optimistic about the forthcoming era of stem cell therapy in IPF, if it surely would come.
Safety and Ethical Concerns
A major controversy about stem cell therapy focuses on its potential adverse effects on human body, such as carcinogenesis and immune intolerance. To date, a few large randomized, controlled trials using commercially-available MSCs intravenously (e.g. 107 cells per each injection) have not shown any excessive and adverse effects with respect to human bodies [62, 63] . However, there is little knowledge about the safety of MSC engraftment in humans with a higher dose, intratracheally or through a pulmonary artery catheter. MSC engraftment could aggravate collagen-induced arthritis by activating IL-6 production and Th17 differentiation [52] . Therefore, we must always keep alert of these possible side effects in clinical trials or clinical uses. The production, collection, culture and growth, genetic modification, transportation and final usage of stem cells are obliged to be kept in accordance with international ethical guidelines and regional laws [71] .
Maximizing the Effects of Stem Cell Engraftment
There are many issues to be taken account prior to the use of stem cells to treat lung diseases. Before it becomes a THERAPY for patients and no longer a METHOD for mice, stem cell engraftment should be scrutinized for indications and contraindications. Other major considerations include the purpose of the engraftment, which cell to engraft and how to perform it, the potency of engraftment, will the engraft form tumors, will cells be rejected, could cells cause undesirable damage, should cell be genetically modified as a gene vehicle, and so on [72] . For example, either intravenous or intratracheal administration of stem cells could diminish bleomy-cininduced pulmonary fibrosis. The optimal giving route should be investigated and fixed by carefully-designed comparison studies. It is recommended that the dosing parameters and giving route, the survival, growth and differentiation of exogenous stem cells be optimized in vivo by clinical trials, so as to offer patients with therapeutic benefits at relatively little risk [73] . These considerations are also important for conceiving clinical trials, in case that there would be increasing number of clinical studies on this issue, regardless of the final results of the preliminary studies. Except for transplanted MSCs, there are also evidences that lung resident stem/progenitor cells contribute to lung repair and regeneration [10, 11, 29, 30] . Chemicals, cytokines and signaling pathways such as ATRA, KGF, Wnt/beta-catenin signaling pathway regulates the in vivo and in vitro differentiation of stem cells [74] [75] [76] [77] . Further studies are necessitated to activate the regenerative potential of endogenous lung stem cells. However, this aspect of stem cell manipulation has always been neglected. Grove et al (2002) have shown that BM-MSCs are easily manipulated with endogenous genes and form lung epithelia in vivo [78] . The authors declare that using bone marrow stem cells as a vector for gene delivery has several advantages, including their accessibility, their easily homing to the inflamed lung tissue via intratracheal injection or by migration after intravenous injecttion, the feasibility to be manipulated in vitro, and their low immunogenicity and high host compatibility [78] . MSCs carrying CFTR genes do well differentiate into lung epithelial cells and produce epithelial marker such as surface proteins [79] . A more recent study demonstrated that engraftment of BM-MSCs expressing keratinocyte growth factor (KGF) gene protects from bleomycin-induced pulmonary fibrosis in vivo [80] . It is no longer unimaginable that genetically modified MSCs, would act well as therapeutic gene vehicles targeting key fibrotic signals such as TGF-beta1, Wnt/beta-catenin or Notch [81] .
Lung tissue engineering has been available, since stem cells could be adequately conditioned to differentiate into both lung epithelial cells and matrix cells. By isolation, culture and stimulation, Macchiarini et al (2008) successfully used a patient's epithelial cells and MSC-derived chondrocytes to generate a bioengineered trachea, which were then transplanted and substituted the previously ruined trachea [82] . The xenograft functioned sufficiently as the conducting airway without any need for intake of immunosuppressants. There are also observations that fetal lung cells imbedded in matrigel sponges are able to form the branching airway structures [83, 84] . However, as compared with the trachea, the lung is a far more delicate system that consists of 16 grades of bronchi, numerous blood vessels and capillaries and more than 40 cell types. In this scenario, we are technically challenged by bioengineering of this sophisticated, three-dimensional architecture [85] . It demands revolutionary advances in stem cell researches, biomaterials, developmental biology, biophysics and biological chemistry, to realize the final success of creating a whole lung with stem cells. This is indeed a long way to go.
CONCLUSION
In conclusion, IPF is still a relentless disease with few effective therapies. Pifernidone slows, but does not reverse the progressive step of IPF. In another respect, stem cells possess the biological properties of recruiting, paracrine, immunosuppressive and differentiation in the lung. Engraftment of various kinds of stem cells alleviates or prevents from lung fibrosis in animal models. Clinical trials are also on the way to explore the safety and therapeutic significance of mesenchymal stem cells in IPF patients. The bench-to-bedside translation has just begun. It is worthy to anticipate that these trials may open a new gate towards curing of IPF.
